CEP164

Across TCGA pan-cancer cohorts, CEP164 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CEP164 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher CEP164 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CEP164 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, UCEC, and LUSC are the cancer types where CEP164 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	III,IV	0.322	0.745	<.001	17	view →
UCEC	DFS	Median	All	0.955	0.827	.018	12	view →
LUSC	OS	Median	II,III,IV	0.214	0.633	.014	11	view →
COAD	DFS	Median	All	0.195	0.507	.030	2	view →
LUAD	OS	Median	All	0.579	0.814	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CEP164–SKCM (OS)

Open the SKCM breakdown →